Birgitta van Bodegraven

Birgitta van Bodegraven

Auto-generated profile, based on publicly available information

Birgitta van Bodegraven

Department of Research and Publishing, British Association of Dermatologists , London

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2022 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
JJJilse Joshy
Jilse Joshy
KMKhaylen Mistry
Khaylen Mistry
NLNick J. Levell
Nick J. Levell
BBBirgitta Bodegraven
Birgitta Bodegraven
SVSally Vernon
Sally Vernon
ZVZoe Claire Venables
Zoe Claire Venables

15 January 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
BBBirgitta van Bodegraven
Birgitta van Bodegraven
VPVictoria Palin
Victoria Palin
CMChirag Mistry
Chirag Mistry
MSMatthew Sperrin
Matthew Sperrin
AWAndrew White
Andrew White
VSVictoria van Staa
Victoria van Staa
Objective Determine the association of incident antibiotic prescribing levels for common infections with infection-related complications and hospitalisations by comparing high with low prescribing general practitioner practices. Design retrospective cohort study Retrospective cohort study. Data source UK primary care records from the Clinical Practice Research Datalink (CPRD GOLD) and SAIL Databank (SAIL) linked with Hospital Episode Statistics (HES) data, including 546 CPRD, 346 CPRD-HES and 338 SAIL-HES practices. Exposures Initial general practice visit for one of six common infections and the proportion of antibiotic prescribing in each practice. Main outcome measures Incidence of infection-related complications (as recorded in general practice) or infection-related hospital admission within 30 days after consultation for a common infection. Results A practice with 10.4% higher antibiotic prescribing (the IQR) was associated with a 5.7% lower rate of infection-related hospital admissions (adjusted analysis, 95% CI 3.3% to 8.0%). The association varied by infection with larger associations in hospital admissions with lower respiratory tract infection (16.1%; 95% CI 12.4% to 19.7%) and urinary tract infection (14.7%; 95% CI 7.6% to 21.1%) and smaller association in hospital admissions for upper respiratory tract infection (6.5%; 95% CI 3.5% to 9.5%) The association of antibiotic prescribing levels and hospital admission was largest in patients aged 18–39 years (8.6%; 95% CI 4.0% to 13.0%) and smallest in the elderly aged 75+ years (0.3%; 95% CI −3.4% to 3.9%). Conclusions There is an association between lower levels of practice level antibiotic prescribing and higher infection-related hospital admissions. Indiscriminately reducing antibiotic prescribing may lead to harm. Greater focus is needed to optimise antibiotic use by reducing inappropriate antibiotic prescribing and better targeting antibiotics to patients at high risk of infection-related complications.

1 April 2023 in Clinical and Experimental Dermatology
Verified
Journal Article
Open access
PDF file
JJJilse Joshy
Jilse Joshy
BBBirgitta van Bodegraven
Birgitta van Bodegraven
KMKhaylen Mistry
Khaylen Mistry
PCPaul Craig
Paul Craig
NRNeil Rajan
Neil Rajan
ZVZoe C Venables
Zoe C Venables
Background: Porocarcinoma (PC) is a cutaneous malignancy that differentiates towards (possibly arises from) the sweat ducts and glands. Lack of histological diagnostic markers makes clinical and pathological diagnosis complex. The limited data available suggest the incidence is increasing; however, this remains to be established in national epidemiological studies. Objectives: To report the incidence, treatment and survival of patients with PC in England from 1 January 2013 to 31 December 2018 using national cancer registry data. Methods: PC diagnoses in England during 2013–2018 were identified from the National Disease Registration Service using morphology and behaviour codes. These were registered from routinely collected pathology reports and cancer outcomes and services datasets. The 2013 European age standardized incidence rates (EASRs), Kaplan–Meier all-cause survival and log-rank test were calculated. Results: In total, 738 tumours (396 in males and 342 in females) were diagnosed. The median age at diagnosis was 82 years old (interquartile range 74–88). The most frequently affected site were lower limbs (35.4%), followed by the face (16%). The majority of the cohort received surgical excision (73.0%). The Kaplan–Meier all-cause survival was 45.4% at 5 years, which was lower than in previous studies. The EASR for the whole population was 0.25 [95% confidence interval (CI) 0.23–0.27] per 100 000 person-years (PY)]. PC incidence rates in the East of England (EASR of 0.54, 95% CI 0.47–0.63 per 100 000 PY) were three times higher than the South West (EASR of 0.14, 95% CI 0.10–0.19 per 100 000 PY) where the regional rates were the lowest. Conclusions: This study shows that there is large variation in the EASRs of PC across England. This may reflect differences in how PC is diagnosed and registered in different regions in England. These data support national assessment of the management of PC, which will inform future studies and guideline development.

12 May 2023 in Skin Health and Disease
Verified
Journal Article
Open access
MSManu Shah
Manu Shah
BBBirgitta van Bodegraven
Birgitta van Bodegraven
Background: Male genital lichen sclerosus (MGLS) is a chronic inflammatory condition most often seen in uncircumcised men. It has an association with squamous cell carcinoma of the penis and causes significant morbidity in many men. It may present with a range of symptoms, notably male dyspareunia. The full range of symptoms in individuals has yet to be elucidated. Aim: To identify the range and severity of patient's symptoms using a questionnaire to quantify symptoms, including sexual function and urinary symptoms. Patients with MGLS were compared against patients diagnosed with other genital skin conditions (non-MGLS). Methods: Retrospective review of patients attending a specialist male genital skin clinic. A questionnaire, where symptoms were ranked between 0 (not present/no effect) and 10 (severe effect) was presented as part of the clinical assessment. Clinical diagnosis of MGLS or non-MGLS was made at the assessment. Results: Sixty four patients attending the clinic completed the questionnaire, and 50 patients were diagnosed with MGLS. Splitting of skin (61.0%), soreness (61.0%), and unusual appearance or colour of penis (57.8%) were the most frequently reported physical symptoms in patients with MGLS. Non-MGLS patients reported these same symptoms in 35.7%, 35.7%, and 50.0% of cases respectively. Conclusion: Administering a simple numeric questionnaire for patients with MGLS has revealed multiple symptoms experienced by most patients. Scoring these symptoms allows the clinician to focus on the problems that most concern the individual patient, rather than just focussing on the physician's assessment of clinical disease.

1 December 2025 in British Journal of Dermatology
Verified
Journal Article
Closed access
KQKate Quirke
Kate Quirke
JPJames Powell
James Powell
DKDimitrios Karponis
Dimitrios Karponis
MPMartyn Patel
Martyn Patel
BBBirgitta van Bodegraven
Birgitta van Bodegraven
ZVZoe C Venables
Zoe C Venables
This study assesses incidence, and overall and net survival in patients with lentigo maligna (LM) in England. Data show excellent 5-year net survival for all ages (> 100%), but overall survival in those aged 80+ years is only 60.4%, reflecting the impact of comorbidities and limited life expectancy. These findings highlight the need for LM management guidelines to incorporate frailty assessment and support shared decision making in older adults, including consideration of nonsurgical approaches.

15 December 2025 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
ECEleanor Clarke
Eleanor Clarke
BBBirgitta van Bodegraven
Birgitta van Bodegraven
ASAlexa R Shipman
Alexa R Shipman
A retrospective descriptive cohort study was performed using data from the British Association of Dermatologists Biologics and Immunomodulator Register, a registry pharmacovigilance study in the UK and Ireland looking at people with a diagnosis of psoriasis. There was no statistically significant association between methotrexate (MTX) exposure and fibrotic interstitial lung disease (fILD) occurrence. Among people exposed to MTX for psoriasis, there were 2.5 fewer fibrosis cases per 10 000 person-years compared with the nonexposed group. These findings are consistent with the evolving body of evidence challenging the perceived link between MTX exposure and development of fILD and support that chest radiography is probably unnecessary in dermatology drug monitoring clinics.